Detalhe da pesquisa
1.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet
; 401(10370): 25-37, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493791
2.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495881
3.
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
N Engl J Med
; 384(13): 1227-1239, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789011
4.
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.
Rheumatology (Oxford)
; 2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341669
5.
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 2024 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38218744
6.
A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies.
J Am Acad Dermatol
; 90(2): 349-357, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37852305
7.
Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data.
J Am Acad Dermatol
; 90(5): 935-944, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38147900
8.
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
J Am Acad Dermatol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447700
9.
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 90(3): 485-493, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37852306
10.
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
J Am Acad Dermatol
; 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588819
11.
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
J Am Acad Dermatol
; 90(4): 775-782, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38122848
12.
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry.
Clin Exp Dermatol
; 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38733332
13.
A New Tool to Improve Communication Between Hidradenitis Suppurativa Patients and Health Care Providers.
J Drugs Dermatol
; 23(2): 105-109, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38306140
14.
Expression of IL-4 in Tumors: A Safety Surrogate to Predict Cancer Survival Associated With Biologic Therapies.
J Drugs Dermatol
; 23(4): e118-e119, 2024 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38564398
15.
A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib.
J Drugs Dermatol
; 23(2): e60-e63, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38306123
16.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ann Rheum Dis
; 82(11): 1404-1414, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696588
17.
Sleep Problems in Patients With Psoriatic Arthritis: A Systematic Literature Review and Metaanalysis.
J Rheumatol
; 2023 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37127321
18.
Safety of guselkumab treatment for up to 5â years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
Br J Dermatol
; 189(1): 42-52, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37022762
19.
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.
Br J Dermatol
; 189(6): 685-694, 2023 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37562034
20.
Cardiovascular Risk Management in Patients Treated with JAK Inhibitors.
J Cardiovasc Pharmacol
; 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37566808